Skip to main content
TRAX logo

TRAX · First Tracks Biotherapeutics, Inc.

Track TRAX — free
$44.79 +0.29 (+0.65%)
Market Cap
$1.87B
Shares
42.02M
Volume · Nov 19 98.53K Avg daily vol (3M) 827.63K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$44.50 Open$43.17 Day$43.17–45.48 Available close range$15.32–52.33 Avg vol 30d998K Short int5.1M · 12.0% of shares · 6.5d Short vol43% Last earningsOct 12, 2026 DataApr 2026–Nov 2026 Filing10-Q · Nov 3

The closing range uses available history since Apr 6, 2026; less than a full year is stored.

Latest documents

2026
Nov 17
Investor event
Celiac candidate nearly prevented gluten damage in trial

First Tracks said its lead celiac drug nearly prevented gluten-driven villous damage in a challenge study. Its second celiac trial, in more severe patients, reads out in the first quarter of next year.

3 source passages
we saw, in the context of an intense gluten challenge, almost a full prevention of deterioration That reads out in the first quarter of next year. the patients we're enrolling in the second cohort are more severe Open the document at this passage
Nov 16
Investor event
AMB033 celiac results support late-stage trials in 2027

First Tracks Bio reported AMB033 produced statistically significant celiac gluten-challenge results across histology and patient-reported symptoms, and committed to late-stage celiac trials in 2027. The healing-cohort readout is expected in the first quarter of 2027.

5 source passages
So First Tracks Bio, we are still technically a young company. One is AMB033. But what I'll start with is we recently announced statistically significant and compelling results, highly compelling results in a celiac trial in a gluten challenge frame. And we have committed publicly that we'll start late-stage trials in 2027. Cohort 2 has completed enrollment, and we will have those study results in the first quarter of 2027. Open the document at this passage
Nov 10
Investor event
CD122 celiac challenge shows best-in-class delta

First Tracks said its CD122 antagonist produced best-in-class celiac challenge results, plans four indications and late-stage celiac trials in 2027, and reported over $350 million in cash.

6 source passages
Our next presenting company, First Tracks from the company. So it is an antagonist of CD122, which presents in a receptor complex, either dimeric or trimeric receptor complex, on various types of immune cells. That's best in class in terms of the delta. A year from now, we will be in four indications being developed in at least two therapeutic areas for this drug. We'll be moving to late-stage trials for celiac disease and hopefully have released equally positive data in EOE. we are well-funded with over $350 million of cash sitting here today. I think we have enough assurance at this point that we will be able to start late-stage studies in 2027. Open the document at this passage
Nov 3
Quarterly report 10-Q FY2026 Q3, ended Sep 30
ANB033 shows positive celiac histology and symptom results

First Tracks Biotherapeutics said ANB033’s Phase 1b celiac Cohort 1 met histologic and symptom endpoints, with placebo-adjusted Vh:Cd improvement of +0.49 (p=0.009) and IEL reduction of -20.03 (p<0.001). Cash and cash equivalents totaled $155.6 million as of September 30, 2026.

Net loss $31.36M Diluted EPS -$0.88
Read from the MD&A section
5 source passages
First Tracks Biotherapeutics and EcoR1 Capital Fund Qualified, L.P. (“EcoR1”) entered into a securities purchase agreement On October 12, 2026, we announced top-line results from Cohort 1 (gluten challenge) of ANB033’s Phase 1b trial in celiac disease. ANB033 demonstrated a statistically significant difference compared to placebo across key histologic endpoints, including least squares (“LS”) mean change in villus height-to-crypt depth (“Vh:Cd”) ratio and intraepithelial lymphocyte (“IEL”) density, as well as symptom endpoints using the Celiac Disease Symptom Diary (“CDSD”). Specifically, ANB033 achieved an LS mean change from baseline in Vh:Cd ratio of -0.17 on ANB033 vs. -0.66 on placebo, a +0.49 placebo-adjusted delta (p=0.009), and an LS mean change from baseline in IEL density of -1.20 on ANB033 vs. +18.83 on placebo, a -20.03 placebo-adjusted delta (p<0.001). Cash and cash equivalents totaled $155.6 million as of September 30, 2026, compared to $311.6 million as of December 31, 2025. Open the document at this passage
Nov 3
Current report 8-K
ANB033 shows celiac protection; $200 million placement completed

First Tracks Biotherapeutics said ANB033 achieved statistically significant protection against gluten-induced intestinal damage and symptoms in a celiac disease Phase 1b cohort. It also completed a $200 million private placement, resulting in $343 million pro forma cash.

Financial results
2 source passages
ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms in Cohort 1 (gluten challenge) of Phase 1b trial in celiac disease (CeD) Completed private placement with $200 million in gross proceeds; pro forma cash of $343 million Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$149.80M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-5.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$155.63M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+28.4%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
12.0%
Latest settlement · 6.5 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Very Strong Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 50-day avg +11%
above
RSI (14) 50
neutral
MACD trend Negative
52-week position 79%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +4%
trailing
6-month return +179%
trailing
Relative strength +182%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+21% holders QoQ · +49 funds added
Insider flow Distributing
Net -$1.8M over 90 days · 100% sells
Short interest Falling
12.03% of shares out · ▼ -27.3% MoM · 6.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
182 holders — 13F breadth
Squeeze score 68
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 122%
annualized · 1-yr
Max drawdown −40%
past year
ATR 7.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
+11% Bullish
RSI (14)
50 Neutral
MACD trend
Negative Bearish
52-week position
79% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+21% holders QoQ · +49 funds added
Insider flow Distributing
Net -$1.8M over 90 days · 100% sells
Short interest Falling
12.03% of shares out · ▼ -27.3% MoM · 6.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
182 holders — 13F breadth
Price context
position in its available closing range
Range low $15 Now $45 · 79% Range high $52
vs 50-day avg +11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TRAX
First Tracks Biotherapeutics, Inc.
this stock
$1.87B — — — 12.0%
VRTX
Vertex Pharmaceuticals Inc
$136.01B +18.3% +46.2% 34.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$97.81B +22.5% +20.8% 20.9 2.1%
MRNA
Moderna, Inc.
$79.63B +567.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
182
% held
86.2%
Net QoQ
+2.1M sh
Top holder
EcoR1 Capital, LLC
Held Float
View
Held by Funds
Fund positions
167
View
Short & Settlement
Short Interest Falling
Shares short
5.1M
Days to cover
6.5d
Change
-1.9M sh
View
Short Volume
Short vol %
43%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
32
Value
$1.4K
As of
Oct 22, 2026
View
Off-Exchange
Off-exchange %
49.2%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$1.8M
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-166.1M
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 17, 2026
This year
19

First Tracks said its lead celiac drug nearly prevented gluten-driven villous damage in a challenge study. Its second celiac trial, in more severe patients, reads out in the first quarter of next year.

View
Proposed Sales
Value
$1.8M
Shares
39.3K
Filed
Sep 2, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 1, 2026
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
First Tracks Biotherapeutics Anno…
Published
Nov 3, 2026
Upcoming events
2
View

Performance

5D 20D 120D MTD YTD
TRAX -11.9% +4.0% +178.8% -1.3% —
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY -8.0% +9.6% +182.3% +2.1% —
Key facts CIK 2091349 CUSIP 337185102 13F (30d) 178 filings 175 filers Visit website Investor relations